Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase - PubMed (original) (raw)
. 2005 Apr 14;434(7035):913-7.
doi: 10.1038/nature03443.
Affiliations
- PMID: 15829966
- DOI: 10.1038/nature03443
Free article
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Helen E Bryant et al. Nature. 2005.
Free article
Erratum in
- Nature. 2007 May 17;447(7142):346
Abstract
Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage. Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumours. Here, we show that PARP inhibitors trigger gamma-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired. Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells. We exploit this requirement in order to kill BRCA2-deficient tumours by PARP inhibition alone. Treatment with PARP inhibitors is likely to be highly tumour specific, because only the tumours (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination. The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.
Similar articles
- Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S, Thomas HD, Mitchell J, Curtin NJ. Kyle S, et al. Br J Radiol. 2008 Oct;81 Spec No 1:S6-11. doi: 10.1259/bjr/99111297. Br J Radiol. 2008. PMID: 18820000 - Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA, Helleday T. Gottipati P, et al. Cancer Res. 2010 Jul 1;70(13):5389-98. doi: 10.1158/0008-5472.CAN-09-4716. Epub 2010 Jun 15. Cancer Res. 2010. PMID: 20551068 - Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Farmer H, et al. Nature. 2005 Apr 14;434(7035):917-21. doi: 10.1038/nature03445. Nature. 2005. PMID: 15829967 - Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy.
Helleday T, Bryant HE, Schultz N. Helleday T, et al. Cell Cycle. 2005 Sep;4(9):1176-8. doi: 10.4161/cc.4.9.2031. Epub 2005 Sep 12. Cell Cycle. 2005. PMID: 16123586 Review. - The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
Helleday T. Helleday T. Mol Oncol. 2011 Aug;5(4):387-93. doi: 10.1016/j.molonc.2011.07.001. Epub 2011 Jul 22. Mol Oncol. 2011. PMID: 21821475 Free PMC article. Review.
Cited by
- Graph based recurrent network for context specific synthetic lethality prediction.
Jiang Y, Wang J, Zhang Y, Cao Z, Zhang Q, Su J, He S, Bo X. Jiang Y, et al. Sci China Life Sci. 2024 Oct 12. doi: 10.1007/s11427-023-2618-y. Online ahead of print. Sci China Life Sci. 2024. PMID: 39422810 - Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition.
Corti G, Buzo K, Berrino E, Miotto M, Aquilano MC, Lentini M, Bellomo SE, Lorenzato A, Bartolini A, Mauri G, Lazzari L, Russo M, Di Nicolantonio F, Siena S, Marsoni S, Marchiò C, Bardelli A, Arena S. Corti G, et al. NPJ Precis Oncol. 2024 Oct 14;8(1):231. doi: 10.1038/s41698-024-00706-7. NPJ Precis Oncol. 2024. PMID: 39402170 Free PMC article. - Advancing cancer therapy: new frontiers in targeting DNA damage response.
Qian J, Liao G, Chen M, Peng RW, Yan X, Du J, Huang R, Pan M, Lin Y, Gong X, Xu G, Zheng B, Chen C, Yang Z. Qian J, et al. Front Pharmacol. 2024 Sep 20;15:1474337. doi: 10.3389/fphar.2024.1474337. eCollection 2024. Front Pharmacol. 2024. PMID: 39372203 Free PMC article. Review. - PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD/E axis in ovarian cancer.
Xia Y, Huang P, Qian YY, Wang Z, Jin N, Li X, Pan W, Wang SY, Jin P, Drokow EK, Li X, Zhang Q, Zhang Z, Li P, Fang Y, Yang XP, Han Z, Gao QL. Xia Y, et al. J Immunother Cancer. 2024 Oct 4;12(10):e009032. doi: 10.1136/jitc-2024-009032. J Immunother Cancer. 2024. PMID: 39366751 Free PMC article. Clinical Trial. - Radiofrequency ablation: mechanisms and clinical applications.
Wu J, Zhou Z, Huang Y, Deng X, Zheng S, He S, Huang G, Hu B, Shi M, Liao W, Huang N. Wu J, et al. MedComm (2020). 2024 Oct 2;5(10):e746. doi: 10.1002/mco2.746. eCollection 2024 Oct. MedComm (2020). 2024. PMID: 39359691 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous